A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

ConditionsObesity Muscle Loss

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorActimed Therapeutics Ltd

About this trial

Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide (PROACT 1) and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide (PROACT 2).

Eligibility criteria

Qualifiers

None

Disqualifiers

received a GLP-1RA (including semaglutide),

had a hypoglycaemic event,

lost >5 kg weight,

had a HBA1C over 10.0%.

Trial design

Treatments tested in this trial

(S)-pindolol benzoate
Semaglutide
Placebo to (S)-pindolol benzoate

Treatment groups

120 Participants

are divided into 3 treatment groups

Sponsors and collaborators

Actimed Therapeutics Ltd

Lead sponsor

SCIRENT Clinical Research and Science d.o.o.

Collaborator

Source ClinicalTrials.gov